Conclusion Monotherapy with the most used ISs, including glimepiride, glibenclamide, glipizide, and tolbutamide, seems to be associated with increased mortality and cardiovascular risk compared with metformin. Gliclazide and repaglinide appear to be associated with a lower risk than other ISs.Amplify’d from http://www.medscape.comMortality and Cardiovascular Risk Associated With Different Insulin Secretagogues Compared With Metformin in Type … Continue reading Some diabetic Drugs Lead to Increased Death Rates
The randomized trials of vitamin D and cardiovascular disease and diabetes have been, in general, quite inconsistent and inconclusive. Whether the trials are of vitamin D alone or of vitamin D plus calcium, the results have been mixed and generally neutral and null, not showing a clear association. So until we have more evidence from … Continue reading Supplemental Vit D? Meh!
The risk in patients receiving proton pump inhibitors (Nexium ish) was 1.5. There was no increase in risk related to use of H2 receptor blockers (like Tagmet, Zantac etc.)Amplify’d from http://www.medscape.comFrom British Medical Journal Proton Pump Inhibitor Use and Risk of Adverse Cardiovascular Events in Aspirin Treated Patients With First Time Myocardial InfarctionNationwide Propensity Score … Continue reading Proton Pump Inhibitors (Like Prilosec) Increase the Risk of Heart Attack
It has been proposed that carotenoids and retinoids are agents that may prevent cancer and heart disease. 4 years of supplementation, the combination of beta carotene and vitamin A had no benefit and may have had an adverse effect on the incidence of lung cancer and on the risk of death from lung cancer, cardiovascular … Continue reading Supplemental Vitamin A (Carotene) of NO Help!!!
New obesity drug failsAmplify’d from http://www.medscape.comof cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet. 2010; 376(9740):517-23 (ISSN: 1474-547X)Topol EJ; Bousser MG; Fox KA; Creager MA; Despres JP; Easton JD; Hamm CW; Montalescot G; Steg PG; Pearson TA; Cohen E; Gaudin C; Job B; Murphy JH; Bhatt DL; Scripps Translational Science Institute, LRimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet. 2010; 376(9740):517-23 (ISSN: 1474-547X)Topol EJ; Bousser MG; Fox KA; Creager MA; … Continue reading Rimonabant Dropped
Experimental and epidemiological evidence does support a plausible role for improving vitamin D status in CVD prevention in the population at large. cardiovascular disease (CVD) is the number one cause of death, being responsible for approximately 30% of deaths worldwide. Solar UV-B radiation is the major source of vitamin D for humans. A significant proportion … Continue reading Vitamin D and Death